Althea Group Holdings Limited manufactures, sells, and distributes pharmaceutical grade medicinal cannabis in Australia, the United Kingdom, Africa, and Canada.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.27|
|52 Week High||AU$0.23|
|52 Week Low||AU$0.62|
|1 Month Change||4.85%|
|3 Month Change||-18.18%|
|1 Year Change||-44.33%|
|3 Year Change||-45.46%|
|5 Year Change||n/a|
|Change since IPO||-51.79%|
Recent News & Updates
When Will Althea Group Holdings Limited (ASX:AGH) Become Profitable?
We feel now is a pretty good time to analyse Althea Group Holdings Limited's ( ASX:AGH ) business as it appears the...
|AGH||AU Pharmaceuticals||AU Market|
Return vs Industry: AGH underperformed the Australian Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: AGH underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: AGH is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: AGH's weekly volatility (10%) has been stable over the past year.
About the Company
Althea Group Holdings Limited manufactures, sells, and distributes pharmaceutical grade medicinal cannabis in Australia, the United Kingdom, Africa, and Canada. It also offers a range of education, access, and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways through Concierge, an online service, as well as Medic, an online education. In addition, the company provides formulation and manufacturing of recreational cannabis products, such as beverages, edibles, and topicals.
Althea Group Holdings Fundamentals Summary
|AGH fundamental statistics|
Is AGH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AGH income statement (TTM)|
|Cost of Revenue||AU$5.78m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.049|
|Net Profit Margin||-130.38%|
How did AGH perform over the long term?See historical performance and comparison
Is Althea Group Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AGH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AGH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AGH is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: AGH is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AGH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AGH is good value based on its PB Ratio (1.9x) compared to the AU Pharmaceuticals industry average (3.3x).
How is Althea Group Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AGH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AGH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AGH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AGH's revenue (66.6% per year) is forecast to grow faster than the Australian market (5.5% per year).
High Growth Revenue: AGH's revenue (66.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AGH's Return on Equity is forecast to be high in 3 years time
How has Althea Group Holdings performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: AGH is currently unprofitable.
Growing Profit Margin: AGH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if AGH's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare AGH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: AGH has a negative Return on Equity (-35.24%), as it is currently unprofitable.
How is Althea Group Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: AGH's short term assets (A$14.9M) exceed its short term liabilities (A$6.8M).
Long Term Liabilities: AGH's short term assets (A$14.9M) exceed its long term liabilities (A$4.5M).
Debt to Equity History and Analysis
Debt Level: AGH is debt free.
Reducing Debt: AGH has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AGH has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AGH has less than a year of cash runway if free cash flow continues to reduce at historical rates of 42.3% each year
What is Althea Group Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AGH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AGH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AGH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AGH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AGH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Joshua Fegan also known as Josh, serves as Chief Executive Officer and Managing Director at Althea Group Holdings Limited and serves Executive Director since June 21, 2018. Mr. Fegan serves as Chief Ex...
CEO Compensation Analysis
Compensation vs Market: Josh's total compensation ($USD1.09M) is above average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Josh's compensation has increased whilst the company is unprofitable.
Experienced Board: AGH's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31.5%.
Althea Group Holdings Limited's employee growth, exchange listings and data sources
- Name: Althea Group Holdings Limited
- Ticker: AGH
- Exchange: ASX
- Founded: 2016
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$81.282m
- Shares outstanding: 306.73m
- Website: https://www.althea.life
- Althea Group Holdings Limited
- 360 Elizabeth Street
- Suite 2
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 07:01|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.